I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 21% ± 3% | |
| glutamatergic neuron | 3 studies | 29% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 21% ± 3% | |
| glutamatergic neuron | 3 studies | 29% ± 10% |
Insufficient scRNA-seq data for expression of OPRD1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 91% | 380.06 | 2395 / 2642 | 34% | 1.10 | 237 / 705 |
| intestine | 86% | 68.08 | 828 / 966 | 10% | 0.31 | 55 / 527 |
| spleen | 94% | 38.30 | 226 / 241 | 0% | 0 | 0 / 0 |
| pancreas | 82% | 31.89 | 268 / 328 | 6% | 0.21 | 11 / 178 |
| stomach | 77% | 23.64 | 278 / 359 | 7% | 0.44 | 20 / 286 |
| adrenal gland | 41% | 36.75 | 105 / 258 | 40% | 1.77 | 92 / 230 |
| breast | 48% | 21.44 | 220 / 459 | 24% | 1.03 | 265 / 1118 |
| lung | 64% | 20.41 | 368 / 578 | 8% | 0.33 | 91 / 1155 |
| kidney | 61% | 19.00 | 54 / 89 | 1% | 0.03 | 11 / 901 |
| prostate | 59% | 16.80 | 145 / 245 | 2% | 0.04 | 11 / 502 |
| muscle | 59% | 50.46 | 477 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 53% | 13.94 | 488 / 929 | 0% | 0 | 0 / 0 |
| liver | 50% | 13.40 | 114 / 226 | 1% | 0.04 | 3 / 406 |
| skin | 4% | 0.75 | 73 / 1809 | 45% | 3.00 | 214 / 472 |
| thymus | 49% | 13.53 | 321 / 653 | 0% | 0.00 | 1 / 605 |
| adipose | 42% | 11.90 | 509 / 1204 | 0% | 0 | 0 / 0 |
| esophagus | 30% | 8.92 | 439 / 1445 | 8% | 0.32 | 14 / 183 |
| heart | 29% | 6.30 | 246 / 861 | 0% | 0 | 0 / 0 |
| bladder | 19% | 3.62 | 4 / 21 | 4% | 0.10 | 18 / 504 |
| ovary | 20% | 4.65 | 36 / 180 | 1% | 0.01 | 3 / 430 |
| uterus | 9% | 2.07 | 15 / 170 | 7% | 0.15 | 30 / 459 |
| blood vessel | 5% | 1.04 | 64 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.05 | 1 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0032793 | Biological process | positive regulation of CREB transcription factor activity |
| GO_0007218 | Biological process | neuropeptide signaling pathway |
| GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
| GO_0010629 | Biological process | negative regulation of gene expression |
| GO_0051924 | Biological process | regulation of calcium ion transport |
| GO_0008344 | Biological process | adult locomotory behavior |
| GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
| GO_0031333 | Biological process | negative regulation of protein-containing complex assembly |
| GO_0071363 | Biological process | cellular response to growth factor stimulus |
| GO_0051881 | Biological process | regulation of mitochondrial membrane potential |
| GO_0006955 | Biological process | immune response |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
| GO_0042755 | Biological process | eating behavior |
| GO_0035094 | Biological process | response to nicotine |
| GO_0007187 | Biological process | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger |
| GO_0097237 | Biological process | cellular response to toxic substance |
| GO_0038003 | Biological process | G protein-coupled opioid receptor signaling pathway |
| GO_0071456 | Biological process | cellular response to hypoxia |
| GO_0098992 | Cellular component | neuronal dense core vesicle |
| GO_0098839 | Cellular component | postsynaptic density membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0097444 | Cellular component | spine apparatus |
| GO_0030672 | Cellular component | synaptic vesicle membrane |
| GO_0043679 | Cellular component | axon terminus |
| GO_0043005 | Cellular component | neuron projection |
| GO_0042734 | Cellular component | presynaptic membrane |
| GO_0032590 | Cellular component | dendrite membrane |
| GO_0004985 | Molecular function | G protein-coupled opioid receptor activity |
| GO_0038046 | Molecular function | G protein-coupled enkephalin receptor activity |
| GO_0042923 | Molecular function | neuropeptide binding |
| GO_0033612 | Molecular function | receptor serine/threonine kinase binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | OPRD1 |
| Protein name | Opioid receptor delta 1 isoform DOR-1D Opioid receptor delta 1 isoform DOR-1B Opioid receptor delta 1 isoform DOR-1C Opioid receptor delta 1 isoform DOR-1E Delta-type opioid receptor (D-OR-1) (DOR-1) |
| Synonyms | DOP DOR1 DOR OPRD |
| Description | FUNCTION: G-protein coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. . |
| Accessions | P41143 A0A346G5W5 ENST00000234961.7 A0A346G5W7 A0A346G5W8 A0A346G5W6 |
